Kala - KALA

La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Kala Bio a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Kala Bio..

Kala Bio (NASDAQ:KALA) Azioni, Catena delle Opzioni

Kala Bio

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Kala Bio Inc

KALAMAZOO RESOURCES by KALAMAZOO RESOURCES LTD.

Kalamazoo Resources Ltd

Kalao

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics Inc

Trading Ideas

MCHP

Live On CNBC Jenny Harrington Announces Bought Microchip Technology

RBC Capital analyst Gerard Cassidy maintains U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) with a Outperform and lowers the price target from $57 to $50.

News

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on U.S. Bancorp, Lowers Price Target to $50

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/17064141/Ruanyun-0417-900x600-1.png" alt="" class="wp-image-10878" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/17064141/Ruanyun-0417-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/17064141/Ruanyun-0417-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/17064141/Ruanyun-0417-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The company's AI-based homework and testing apps and 15.1 million users have helped it to stand out from rivals, though the stock looks expensive after a strong post-IPO rally
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>Shares of edtech company Ruanyun jumped up to 80% in their first week of trading, after the company raised $15 million in its Nasdaq IPO</li>
<li>The maker of homework and testing apps may have saturated its home market in Jiangxi province, and will need to expand nationally to maintain its rapid growth</li>
</ul>
After a chilling crackdown that wiped out dozens of companies overnight, China edtech is suddenly roaring back. While some companies are thriving on adult education and other areas still allowed post-crackdown, others are feasting on government-fueled growing demand from schools for more AI technology and content.
Last December, the country's education minister declared AI was the "golden key" for the country's educational system. Squirrel AI, the largest of the AI edtech companies, has raised $180 million and opened 2,000 learning centers across China and plans to open 2,000 more. Its rapid growth has pushed its value above $1 billion, making it an edtech "unicorn."
A smaller company finding a comfortable spot in the emerging AI edtech space is&nbsp;Ruanyun Edai Technology Inc.&nbsp;(RYET.US) whose shares shot up over 80% in the first week after the company's April 8 IPO on the Nasdaq, which&nbsp;<a href="https://www.globenewswire.com/news-release/2025/04/08/3057295/0/en/Ruanyun-Edai-Technology-Inc-Announces-Pricing-of-Initial-Public-Offering.html">raised</a>&nbsp;a modest $15 million. The shares have held most of the gains since then, despite recent market volatility, and were up about 50% from their $4 listing price at Wednesday's close.
Despite its strong debut, Ruanyun looks like a risky bet in many ways. Its cash flow is negative, it has just two major customers, down from a previous three, and its revenue fell sharply in its latest reporting period. The $15 million should help to cover the company's ongoing losses and negative cash flow, as it searches for a path to sustainability.
Ruanyun specializes in tech for primary and secondary school students, or K-12, which was the focus of the regulatory shift that wiped out an entire industry when the Ministry of Education banned after-school tutoring for profit in 2021. While private companies are banned from directly offering such services to students, they are still allowed to provide products and services to schools and government-owned institutions that provide services to schools, which is what Ruanyun does.
The company's customers are almost entirely in Jiangxi, an inland, less affluent province with an economy roughly the size of Norway. Co-founders Fu Yan and Zhao Cong are both alumni of Indiana University and veterans of a since-failed New York-based adtech firm, IgnitionOne.
The pair established Ruanyun in 2012, branching into AI databases and paperless testing centers in 2017 and customized homework exercise books in 2020. The company's most recent revenue and profits aren't exactly inspiring. Its revenue was flat in its fiscal year through March 2024. But then it suddenly dropped 35% to 4.1 million yuan ($561,000) in the six months to last September, the first half of its fiscal year, from 6.3 million yuan a year earlier, as it blamed a change in its marketing strategy.
Meantime, its net loss widened in the fiscal year through March 2024, but then fell considerably to 680,000 yuan in the six months through last September from 1.5 million yuan a year earlier.
Ruanyun's two main products are its SmartHomework system and SmartExam platform. SmartHomework relies on a company database with 10 billion data points generated by 15.1 million students from 16,700 schools, 80% in Jiangxi, to provide exercise books customized for each student. The market for such personalized homework books was worth about 80 billion yuan in 2022, according to internal company estimates.
<h4 class="wp-block-heading">Bigger buyers</h4>
After the government crackdown on after-school tutoring, Ruanyun had to start selling its products to schools and other authorized government institutions rather than directly to students. It now supplies those large buyers with its core products, along with AI learning centers, including tablets and printers.
Its SmartExam product covers all 11 subjects in the gaokao, China's national college entrance exam. Ruanyun also develops test contents and computerized testing centers, facial recognition cameras and hardware designed to keep students from cheating.
Despite its relatively strong positioning, the company's performance has been somewhat volatile, as reflected by its falling revenue. In 2020, Ruanyun built nine testing centers in Nanchang, Jiangxi's capital, and 58 more sites from 2020 to 2022. But only one new site was completed between 2022 and March 2024.
In the six months through March 2024, two major customers accounted for a combined 70% of total revenues, down from three major customers that accounted for a combined 80% in the fiscal year through March 2023. That shows that a diversified revenue stream is not one of the company's strengths, reflecting its reliance on selling to just a handful of large customers in a single province.
In December 2020, Jiangxi Xinhua Distribution Group Co. Ltd made Ruanyun a strategic business partner, providing students in the province with standard subscriptions for the company's personalized exercise books. But paying users for these fell from 26,900 in the year to March 2023 to 20,200 in the 12 months to March 2024. Still, registered members increased from 14.3 million to 15.1 million over that time, providing an important resource by contributing data for use in the company's AI database.
Nearly 60% of the company's revenue in the year through March 2024 came from digitization services, paid by publishers for converting publications to digital format, with the figure growing from $4.5 million in the year to March 2023 to $5.2 million in the next fiscal year.
Platform development revenue for its SmartHomework solution increased by 137% to $3.1 million in its fiscal year through March 2024 from $1.8 million the previous year, due partly to expansion beyond Jiangxi, according to the prospectus.
While Ruanyun's credentials as an AI company may be somewhat debatable, that may be less important as long as its pedigree helps it expand outside Jiangxi province. One of its biggest selling points lies in its strong ties to an entire province, where its services are integrated within the K-12 education system.
But rival companies may have similar relationships in other provinces, which could put a crimp on Ruanyun's expansion plans. Such rivals could include Squirrel AI, as well as K-12 tutoring firm Zuoyebang Education Technology, and Tencent-backed Huohua Siwei, all of which are chasing similar customers in the post-crackdown era. In the listed company realm, stalwart&nbsp;New Oriental Education&nbsp;(EDU.US; 9901.HK) recently brought AI expert Dr. Yue Zhuge onto its board, and&nbsp;TAL Education&nbsp;(TAL.US) recently credited its AI learning devices for helping to fuel 62.4% growth in its latest quarterly results.
Following its post-IPO gains, Ruanyun's shares look a bit expensive with a price-to-sales (P/S) ratio of 33.8, compared to TAL's 2.92 and New Oriental's 1.57. That means Ruanyun's post-IPO rally could be short-lived, unless it can find a way to quickly turbocharge its revenue to bring its ratio down to a more realistic level in line with its much larger peers.

Equities

Education

IPOs

Opinion

Tech

A Stock To Watch As China Edtech Rejuvenates With AI Makeover

Scotiabank analyst John Zamparo maintains Metro (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MRU#TSX">MRU</a>) with a Sector Outperform and raises the price target from C$100 to C$111.

TSX:MRU

Scotiabank Maintains Sector Outperform on Metro, Raises Price Target to C$111

Macro Economic Events

Politics

Global

Economics

General

S&P 500 Futures See Volume, President Trump And Italy's Giorgia Meloni End Initial Press Conference, Leaders Express Their Intentions To Come Up With Trade Deal For Both Countries To Prosper During Conversations

Scotiabank analyst Himanshu Gupta maintains FirstService (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSV#NASDAQ">FSV</a>) with a Sector Perform and lowers the price target from $217.5 to $210.

Scotiabank Maintains Sector Perform on FirstService, Lowers Price Target to $210

RBC Capital analyst Jon Arfstrom maintains First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) with a Outperform and lowers the price target from $24 to $22.

RBC Capital Maintains Outperform on First Horizon, Lowers Price Target to $22

AVGO

Live On CNBC Bill Baruch Buys More Broadcom

Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) has outperformed the market over the past 5 years by 21.78% on an annualized basis producing an average annual return of 35.84%. Currently, Murphy USA has a market capitalization of $10.03 billion. 
Buying $1000 In MUSA: If an investor had bought $1000 of MUSA stock 5 years ago, it would be worth $4,652.31 today based on a price of $506.46 for MUSA at the time of writing.
<h3>Murphy USA's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744906632_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MUSA

$1000 Invested In Murphy USA 5 Years Ago Would Be Worth This Much Today

RBC Capital analyst Gerard Cassidy maintains Citizens Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) with a Outperform and lowers the price target from $50 to $44.

RBC Capital Maintains Outperform on Citizens Financial Group, Lowers Price Target to $44

WIIM

NioCorp shares are trading lower after the company announced the pricing of a $20 million underwritten public offering.

RBC Capital analyst Walter Spracklin maintains CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Sector Perform and lowers the price target from $31 to $30.

RBC Capital Maintains Sector Perform on CSX, Lowers Price Target to $30

Morgan Stanley analyst Brian Nowak maintains Yelp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) with a Underweight and lowers the price target from $35 to $30.

YELP

Morgan Stanley Maintains Underweight on Yelp, Lowers Price Target to $30

Oil is trading higher following new US sanctions on Iranian oil exports.

Morgan Stanley analyst Matthew Cost maintains Webtoon Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) with a Equal-Weight and lowers the price target from $13 to $10.5.

WBTN

Morgan Stanley Maintains Equal-Weight on Webtoon Entertainment, Lowers Price Target to $10.5

Wells Fargo analyst Aaron Rakers maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Overweight and lowers the price target from $140 to $120.

Wells Fargo Maintains Overweight on Advanced Micro Devices, Lowers Price Target to $120

RBC Capital analyst Shagun Singh maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $140 to $145.

RBC Capital Maintains Outperform on Abbott Laboratories, Raises Price Target to $145

Morgan Stanley analyst Pamela Kaufman maintains Vital Farms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VITL#NASDAQ">VITL</a>) with a Overweight and lowers the price target from $40 to $39.

VITL

Morgan Stanley Maintains Overweight on Vital Farms, Lowers Price Target to $39

Adagio Medical Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares are trading higher by 124% to $2.07 during Thursday&#8217;s session after the FDA granted Breakthrough Device Designation for the <a href="https://www.benzinga.com/pressreleases/25/04/b44861813/adagio-medical-holdings-inc-receives-fda-breakthrough-device-designation-for-the-vclastm-cryoablat">vCLAS cryoablation system</a>.
What To Know: Adagio Medical says the system targets drug-resistant, recurrent, sustained monomorphic ventricular tachycardia (VT) in patients with ischemic or non-ischemic structural heart disease. The device is designed to improve VT ablation safety and outcomes.
This designation grants Adagio priority FDA review and enhanced support during the premarket phase. It also reflects promising early data from Adagio's European CRYOCURE-VT study. The device is meanwhile under investigation in the U.S. through the FULCRUM-VT trial, enrolling 206 patients.
Adagio CEO Todd Usen called the designation a major milestone, citing unmet needs in VT treatment. While already approved in Europe, the device remains investigational in the U.S., with plans to pursue premarket approval following study completion.
Read Also: <a href="https://www.benzinga.com/news/25/04/44863298/whats-going-on-with-avis-budget-group-car-stock">What&#8217;s Going On With Avis Budget Group Stock?</a>
<h2 class="wp-block-heading">How To Buy ADGM Stock</h2>
By now you're likely curious about how to participate in the market for Adagio Medical Holdings &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Adagio Medical Holdings, which is trading at $2.23 as of publishing time, $100 would buy you 48.31 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ADGM has a 52-week high of $9.34 and a 52-week low of $0.62.

ADGM

Why Adagio Medical Holdings (ADGM) Stock Is Skyrocketing

Wells Fargo analyst Joseph Quatrochi maintains ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) with a Overweight and lowers the price target from $860 to $840.

Comments

Kala Bio

Kala Bio (KALA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO